Previous 10 | Next 10 |
2024-02-22 21:08:06 ET BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Conference Call February 22, 2024, 04:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and Chief Executive Officer Henry Fuchs - Presi...
2024-02-22 16:07:42 ET More on BioMarin Pharmaceutical BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest? BioMarin Pharmaceutical Q4 2023 Earnings Preview Paul Singer's Elliott Management adds ETSY, CCI, MTCH; offloads NI, ARM, NE See...
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 PR Newswire Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y...
2024-02-21 17:20:47 ET More on BioMarin Pharmaceutical BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest? Paul Singer's Elliott Management adds ETSY, CCI, MTCH; offloads NI, ARM, NE BioMarin may be M&A target with activist Elliott pact - ...
2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...
2024-02-14 16:43:55 ET More on Arm Holdings, BioMarin Pharmaceutical, etc. Howmet Aerospace Inc. 2023 Q4 - Results - Earnings Call Presentation Howmet Aerospace Inc. (HWM) Q4 2023 Earnings Call Transcript Arm Holdings Stock: Valuation Too High For Its Growth Rate ...
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced...
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress PR Newswire New Seven-Year Follow-Up Phase 2 Study Results Showed Durable Hemostati...
2024-01-30 14:30:03 ET Piper Sandler analyst issues UNDERPERFORM recommendation for BMRN on January 30, 2024 02:00PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $89.795 at issue of the analyst recommendation. The overall analyst consensu...
2024-01-21 09:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. U.S. equities rose in ...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Reports Record Financial Results for the First Quarter 2024 PR Newswire First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings pe...
Pegasystems Inc. (PEGA) is expected to report $0.2 for Q1 2024 Masco Corporation (MAS) is expected to report $0.87 for Q1 2024 Avery Dennison Corporation (AVY) is expected to report $2.15 for Q1 2024 Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A...
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexand...